Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
|Articles|May 27, 2016
Perspective Taking
Author(s)Tonya Marie Pan, MA, MS
Advertisement
Editor’s Note: This piece was submitted by a contributing writer and does not represent the views of CURE Media Group.
Perspective Taking
What's the difference between a teachable moment
and guilt and shame?
He feels remorse all the same
His body betrayed him
He is still not used to his brain
What can he do differently?
Clearly, he’s not the same
Alone time is a new necessity
Loneliness is his new reality
Advertisement
Related to this article
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
A national survey study of about 200,000 adults, published in Supportive Care in Cancer, found that people caring for someone with cancer had 89% higher odds of frequent mental distress than people who were not caregivers.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
3
Neuro-Oncologist Answers Common Questions About Brain Cancer Diagnosis and Treatment
4
Life After a Prostate Cancer Diagnosis: Why It’s a Pivot, Not an Ending
5